Nutex Health Inc NUTX.OQ NUTX.O is expected to show a rise in quarterly revenue when it reports results on August 14 for the period ending June 30 2025
The Houston Texas-based company is expected to report a 132.0% increase in revenue to $176.475 million from $76.08 million a year ago, according to the mean estimate from 3 analysts, based on LSEG data.
LSEG's mean analyst estimate for Nutex Health Inc is for a loss of $1.58 per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Nutex Health Inc is $225.00, about 60.2% above its last closing price of $89.63
This summary was machine generated August 12 at 20:25 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)